• HOME
  • PIPLINE
  • Platform Technologies
  • Ocular Delivery (Eyedrop Nanoformulation)
Menu
Overview
Platform Technologies
Brain Delivery Ocular Delivery (Eyedrop Nanoformulation) Nucleic Acid Delivery Oral Peptide Delivery Active Targeting Nanoparticle
Brain Disease
NTT-001 (Brain Cancer) DNA Plasmid (IV Injection for PD)
Cancer Therapy
NTT-001 (Brain Cancer) NTT-002 (Metastatic Colorectal Cancer)
Ocular Disease
NTT-003 (Eyedrop Formulation for Wet-AMD) ASO (Eyedrop Formulation for Wet-AMD) Therapeutic Peptide (Eyedrop Formulation for Dry-AMD)
Ocular Delivery (Eyedrop Nanoformulation)

Summary

• The MSN eyedrop nanoformulation platform offers a promising non-invasive approach to deliver a wide range of therapeutics, including small molecules, peptides, and nucleic acids (e.g., ASO, DNA) with diverse physicochemical properties (hydrophilic and hydrophobic) to the posterior segment of the eye.
• MSNs with smaller hydrodynamic sizes can effectively cross the blood-ocular barrier and reach the posterior segment via the non-corneal pathway.
• The MSN eyedrop formulation is a clear, transparent, and homogeneous liquid, providing a potential alternative to invasive intravitreal injections for retinal diseases.

 

MSN Distribution in Eyes

• MSNs can effectively reach the posterior segment of the eye and remain for several hours before being cleared within 24 hours.
• They are believed to reach the back of the eye via the non-corneal pathway: conjunctiva → sclera → choroid → retina